ReNeuron (Group)

https://www.reneuron.com

ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need. ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development. The Company is also developing stem cell therapies for other conditions such as critical limb ischaemia, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina such as retinitis pigmentosa. ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell® products for use in academic and commercial research. The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. *

	Start	1997-01-01 established
	Industry	stem cell research
	Industry 2	stem cell therapy
	Person	Hellebø, Olav (ReNeuron 201507 CEO before Clavis Pharma 201108 CEO)
	Person 2	Hunt, Michael (ReNeuron 201507 CFO before 200508 CEO)

	Region	Guildford, Surrey
	Country	United Kingdom (GB)
	Street	10 Nugent Road, Surrey Research Park
	City	GU2 7AF Guildford, Surrey
	Tel	+44-1483-302560
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	GBP
	Annual sales	17,000 (revenues (2012/13) 2013-03-31)
	Profit	-6,300,000 (2013-03-31)
	Cash	3,500,000 (2013-03-31)

		* Document for »About Section«:

		Record changed: 2023-09-25

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for ReNeuron (Group)

[1] BenevolentAI. (9/11/23). "Press Release: Appointment of Catherine Isted, ACMA, as Chief Financial Officer". London....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)